To: Senators Elizabeth Warren & Richard Blumenthal
"We were disappointed that your findings confirmed our concerns about access to affordable insulin as it had been our hope that new, lower cost alternatives and patient assistance programs were beginning to make a dent in this critical problem. We have been working with key stakeholders over the past two years to address this issue and requested information from manufacturers about the availability and use of lower cost options for people with diabetes. To us, it is not enough for these programs to be merely available; patient and clinician education must be expanded to ensure that individuals who desperately need access to lower cost insulin know and understand their options and have easy access to them."
Read the Full Letter
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.